Form 4: National Health Investors Director Acquires Stock Options and Shares Through Dividend Reinvestment
SEC Form 4 Filing
Director Robert A. McCabe Jr. reports acquisition of stock options and shares in National Health Investors through a recent transaction and dividend reinvestment.
Summary
- Robert A. McCabe Jr., a director of National Health Investors Inc. (NHI), reported changes in beneficial ownership of the company's securities.
- On February 23, 2024, McCabe acquired 10,000 stock options with an exercise price of $57.76, expiring on February 23, 2029.
- McCabe also acquired 1,404.05 shares of common stock in 2023 through enrollment in the Dividend Reinvestment Plan.
- Following these transactions, McCabe directly owns 21,148 shares of common stock.
- McCabe also holds multiple stock option grants from previous years.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive as the director is increasing their stake in the company, which is generally a good sign. However, it's a routine transaction.
Positives
- Director's participation in the Dividend Reinvestment Plan indicates confidence in the company's future.
- The acquisition of new stock options aligns the director's interests with those of shareholders.
Industry Context
Directors acquiring company stock and participating in dividend reinvestment plans are generally viewed positively, as it aligns their interests with those of shareholders and demonstrates confidence in the company's prospects within the healthcare REIT sector.
Comparison to Industry Standards
- Comparing director stock ownership and option grants to peers like Welltower (WELL), Ventas (VTR), and Healthpeak Properties (PEAK) can provide context on executive compensation and alignment with shareholder value.
- Dividend reinvestment plans are common among REITs, offering shareholders a convenient way to increase their holdings and benefit from compounding returns.
Stakeholder Impact
- The director's increased stake could positively influence shareholder sentiment.
- Employees may view the director's investment as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/21/2020 | Date of stock options grant with exercise price $90.79, expiring 02/21/2025 |
| 02/25/2021 | Date of stock options grant with exercise price $69.2, expiring 02/25/2026 |
| 02/25/2022 | Date of stock options grant with exercise price $53.41, expiring 02/25/2027 |
| 02/24/2023 | Date of stock options grant with exercise price $54.73, expiring 02/24/2028 |
| 02/23/2024 | Date of recent transaction: acquisition of stock options and reporting date. |
| 02/23/2029 | Expiration date of stock options acquired on 02/23/2024. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.